A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Clinical trial NCT03292172 · TERMINATED
Trial details
- NCT number
- NCT03292172
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-08
- Primary completion
- 2019-02-26
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.